ASLAN Pharmaceuticals Ltd - ADR
ASLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.8M
Close$
$0.04
92.8% downside
Current Fair Value
92.8% downsideOvervalued by 92.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.80 Million |
|---|---|
| Enterprise Value | $13.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.76 |
| Beta | 1.4 |
| Outstanding Shares | 4,667,611 |
Return
| Return on Equity | 194.97% |
|---|---|
| Return on Assets | -166.89% |
| Return on Invested Capital | -2522.12% |
Valuation & Multiples
| P/E Ratio | -0.06 |
|---|---|
| PEG | 0.12 |
| Price to Sales | 0.3 |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 1.12 |
| Enterprise Value to EBIT | -0.38 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.16 |
| Debt to Equity | -1.62 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ASLAN Pharmaceuticals Ltd
CEO: Carl Firth